Imino-urea derivatives

a technology of urea and derivatives, applied in the field of medicine, can solve the problems of unsatisfactory clinical effects, mental illnesses such as depression and anxiety, and the level of 5-hydroxytryptamine is still low

Inactive Publication Date: 2020-10-15
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]The compound or a pharmaceutically acceptable salt thereof has excellent activity for inhibiting indoleamine 2,3-dioxygenase, and the activity is significantly superior to other IDO inhibitors. In addition, by measuring the body weight of mice before and after the administration of the compound or a pharmaceutically acceptable salt thereof, it is found that as compared to other IDO inhibitors, the compound of the present invention or a pharmaceutically acceptable salt thereof can significantly improve the life quality of mice during tumor treatment and significantly reduce side effects. In clinical practice, the compound of the present or a pharmaceutically acceptable salt thereof will improve not only patient's life quality, but also significantly improve patient compliance with medications and medicament effectiveness. The compound of the present invention or a pharmaceutically acceptable salt thereof can significantly improve the learning and memory impairment in animals and enhance learning acquisition ability and spatial memory ability, has positive therapeutic significance for neurodegenerative diseases such as Alzheimer's syndrome, and is superior to other IDO inhibitors. The compound of the present invention or a pharmaceutically acceptable salt thereof can promote the function of DC in stimulation of T cell proliferation, so that it can be used for treating tumor diseases, autoimmune diseases, transplant rejection, and infectious diseases, and it is superior to other IDO inhibitors.DETAILED DESCRIPTION OF THE INVENTION

Problems solved by technology

Although great progress has been made in treatment of tumors in recent years, the clinical efficacy is still unsatisfactory.
It can lower the level of 5-hydroxytryptamine and cause mental illnesses such as depression and anxiety.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Imino-urea derivatives
  • Imino-urea derivatives
  • Imino-urea derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0088]

[0089]Compound 1 (903 mg, 10 mmol) was dissolved in acetone (10 mL), then potassium carbonate (2.76 g, 20 mmol) was added at room temperature, stirred at room temperature for 0.5 h, added dropwise with benzenesulfonyl chloride, stirred at room temperature overnight, quenched with water, and the resultant was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain 900 mg of a white powder.

[0090]Compound 2 (230 mg, 1 mmol) was dissolved in acetonitrile (5 mL), stirred at room temperature for 0.5 h, then added with compound 2a (320 mg, 2 mmol), heated at 60° C. for 24 h, and the resultant was directly evaporated to dryness under reduced pressure, and subjected to purification by pre-HPLC to obtain 210 mg of the desired product.

[0091]Compound 3 (171 mg, 0.5 mmol) was dissolved in dichloromethane (10 mL), stirred at room temperature for 5 min, added with trifluoroacetic acid (5 mL), reacted at room temperature for 2 h, and then the resultant wa...

example 10

[0097]

[0098]Compound 1a (682 mg, 2 mmol) was dissolved in trifluoroacetic acid (13 mL), then 30% H2O2 was added dropwise at room temperature, the mixture was reacted overnight at 50° C., and the reaction solution changed from turbid to clear yellow. After the reaction was completed, the reaction was quenched with a saturated sodium sulfite solution. After KI starch test paper showed clolorless, the resultant was extracted with ethyl acetate (50 mL*2), and the organic phase was dried over anhydrous sodium sulfate, concentrated, and then subjected to purification by column chromatography (petroleum ether:ethyl acetate=1:1) to obtain a pale yellow solid 2a (500 mg, yield 67%).

[0099]Ethylenediamine 1 (30 mg, 0.5 mmol) was added to a solution of Compound 2a (170 mg, 0.5 mmol) in tetrahydrofuran (10 mL), then 1N NaOH (0.4 mL) was added, the reaction solution was stirred at room temperature for 0.5 h, and the reaction solution was directly used to prepare and obtain Compound 2 (120 mg).

[01...

example 11

[0102]

[0103]1,3-Diaminopropane (35 mg, 0.5 mmol) was added to a solution of Compound 1 (170 mg, 0.5 mmol, the synthesis method of which was referred to the synthesis of Compound 2a in XSD3-047 Final report) in tetrahydrofuran (10 mL), the reaction solution was stirred at room temperature for 0.5 h, and the reaction solution was directly used to prepare and obtain the desired product of 130 mg.

[0104]A mixture solution of Compound 2 (130 mg, 0.33 mmol) and Compound 1a (100 mg, 0.33 mmol) in methanol (10 mL) was stirred at room temperature overnight, the reaction solution was concentrated and subjected to purification by column chromatography (petroleum ether:ethyl acetate=1:1) to obtain Compound 3 (78 mg, 45%).

[0105]Trifluoroacetic acid (0.6 mL) was added to a solution of Compound 3 (31 mg, 0.05 mmol) in dichloromethane (3 mL), stirred at room temperature overnight, then adjusted with 1N NaOH solution to pH=12, stirred continuously for 20 min, and the reaction was monitored by LCMS. A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the field of medicines, and in particular to an imino-urea derivative containing a furan structure and a composition thereof. The derivative and the composition thereof can be used in the manufacture of a medicament for treating a disease pathologically characterized by indoleamine 2,3-dioxygenase-mediated tryptophan metabolic pathway. The present invention also relates to a method for preparing the derivative and an intermediate thereof.

Description

TECHNICAL FIELD[0001]The invention relates to the field of medicines, in particular to an imino-urea derivative and a preparation method and a use thereof.BACKGROUND ART[0002]Indoleamine 2,3-dioxygenase, a monomeric enzyme containing heme, is capable of catalyzing the oxicracking of indole ring of L-tryptophan to form kynurenine. The high expression of indoleamine 2,3-dioxygenase results in depletion of local tryptophan in cells, which induces T cell arrest in G1 phase, thereby inhibiting T cell proliferation. On the other hand, the degradation of indoleamine 2,3-dioxygenase-dependent tryptophan leads to an increase in kynurenine level and also induces oxygen free radical-mediated T cell apoptosis. Thirdly, the up-regulation of dendritic cell indoleamine 2,3-dioxygenase expression enhances local regulatory T cell (Treg)-mediated immunosuppression by degrading local tryptophan, thereby promoting peripheral immune tolerance of body to tumor specific antigen. Indoleamine 2,3-dioxygenas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D271/08A61P35/04
CPCC07D271/08A61P35/04A61P25/28A61P35/00A61P27/12A61P25/22A61P25/24A61P31/04A61P31/10A61P31/12A61P33/00A61K31/4245A61P27/02A61P31/00
Inventor ZHANG, GUIMINYAO, JINGCHUNREN, YUSHAN
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products